Skip to main content
Top
Published in: Diabetologia 5/2004

01-05-2004 | Article

Binding of receptor for advanced glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived advanced glycation end products

Authors: J. V. Valencia, M. Mone, C. Koehne, J. Rediske, T. E. Hughes

Published in: Diabetologia | Issue 5/2004

Login to get access

Abstract

Aims/hypothesis

Activation of the receptor for advanced glycation end products (RAGE) reportedly triggers cellular responses implicated in the pathogenesis of diabetes, such as increasing vascular cell adhesion molecule-1 (VCAM-1) expression on vascular endothelial cells and inducing TNF-α secretion by mononuclear cells. The objective of this study was to evaluate whether RAGE binding affinity of AGE-BSAs and cellular activation correlate.

Methods

To produce AGEs with varying glycation, bovine albumin AGEs were prepared with 500 mmol/l of glucose, fructose or ribose at times of incubation from 1 to 12 weeks. In addition, AGE-BSA was generated using either glyoxylic acid or glycolaldehyde. Cellular binding of the AGE-BSAs and the effect on endothelial cell VCAM-1 expression were studied in RAGE-expressing human microvascular endothelial cell line-4 cells. Induction of TNF-α secretion was assessed using RAGE-expressing human peripheral blood mononuclear cells (PBMCs).

Results

Cellular binding of the different AGE preparations correlated well with RAGE affinity. Interestingly, we found that the AGE preparations, which were essentially endotoxin free (≤0.2 ng/mg protein), were incapable of inducing VCAM-1 or TNF-α secretion regardless of RAGE binding affinity, AGE concentration or incubation time. In contrast, the reported RAGE ligand S100b was confirmed to induce VCAM-1 expression on endothelial cells and TNF-α secretion by PBMCs after 24 h of treatment.

Conclusions/interpretation

The results of this study suggest that AGE modification and high RAGE binding affinity are not sufficient to generate pro-inflammatory signalling molecules. Thus, RAGE binding affinity of AGE-BSAs does not seem to correlate with cellular activation. Our findings using AGEs with strong RAGE-binding properties indicate that AGEs may not uniformly play a role in cellular activation.
Literature
1.
go back to reference Hanssen KF (1997) Blood glucose control and microvascular and macrovascular complications in diabetes. Diabetes 46 [Suppl 2]:S101–S103 Hanssen KF (1997) Blood glucose control and microvascular and macrovascular complications in diabetes. Diabetes 46 [Suppl 2]:S101–S103
2.
go back to reference Nishikawa T, Edelstein D, Brownlee M (2000) The missing link: a single unifying mechanism for diabetic complications. Kidney International 58 [Suppl 77]:S26–S30 Nishikawa T, Edelstein D, Brownlee M (2000) The missing link: a single unifying mechanism for diabetic complications. Kidney International 58 [Suppl 77]:S26–S30
3.
go back to reference Ross R (1999) Atherosclerosis- an inflammatory disease. N Engl J Med 340:115–126PubMed Ross R (1999) Atherosclerosis- an inflammatory disease. N Engl J Med 340:115–126PubMed
4.
go back to reference Krieglstein CF, Granger DN (2001) Adhesion molecules and their role in vascular disease. Am J Hypertens 14:44S–54SCrossRefPubMed Krieglstein CF, Granger DN (2001) Adhesion molecules and their role in vascular disease. Am J Hypertens 14:44S–54SCrossRefPubMed
5.
go back to reference Pradhan AD, Ridker PM (2002) Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 23:831–834CrossRefPubMed Pradhan AD, Ridker PM (2002) Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 23:831–834CrossRefPubMed
6.
go back to reference Schrör K (1997) Blood vessel wall interactions in diabetes. Diabetes 46 [Suppl 2]:S115–S118 Schrör K (1997) Blood vessel wall interactions in diabetes. Diabetes 46 [Suppl 2]:S115–S118
7.
go back to reference Schiekofer S, Balletshofer B, Andrassay M, Bierhaus A, Nawroth PP (2000) Endothelial dysfunction in diabetes mellitus. Semin Thromb Hemost 26:503–511CrossRefPubMed Schiekofer S, Balletshofer B, Andrassay M, Bierhaus A, Nawroth PP (2000) Endothelial dysfunction in diabetes mellitus. Semin Thromb Hemost 26:503–511CrossRefPubMed
8.
go back to reference Basta G, Lazzerini G, Massaro M et al. (2002) Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105:816–822 Basta G, Lazzerini G, Massaro M et al. (2002) Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105:816–822
9.
go back to reference Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP (1998) AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus I. The AGE concept. Cardiovasc Res 37:586–600CrossRefPubMed Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP (1998) AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus I. The AGE concept. Cardiovasc Res 37:586–600CrossRefPubMed
10.
go back to reference Dunn JA, McCance DR, Thorpe SR, Lyons TJ, Baynes JW (1991) Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon-(carboxymethyl)hydroxylysine in human skin collagen. Biochemistry 30:1205–1210PubMed Dunn JA, McCance DR, Thorpe SR, Lyons TJ, Baynes JW (1991) Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon-(carboxymethyl)hydroxylysine in human skin collagen. Biochemistry 30:1205–1210PubMed
11.
go back to reference Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW (1995) N-epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34:10872–10878PubMed Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW (1995) N-epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34:10872–10878PubMed
12.
go back to reference Verzijl N, DeGroot J, Oldehinkel E et al. (2000) Age-related accumulation of Maillard reaction products in human articular cartilage collagen. Biochem J 350:381–387PubMed Verzijl N, DeGroot J, Oldehinkel E et al. (2000) Age-related accumulation of Maillard reaction products in human articular cartilage collagen. Biochem J 350:381–387PubMed
13.
go back to reference Schleicher ED, Wagner E, Nerlich AG (1997) Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 99:457–468PubMed Schleicher ED, Wagner E, Nerlich AG (1997) Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 99:457–468PubMed
14.
go back to reference Miyata T, Ishikawa S, Asahi K et al. (1999) 2-Isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage. FEBS Lett 445:202–206CrossRefPubMed Miyata T, Ishikawa S, Asahi K et al. (1999) 2-Isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage. FEBS Lett 445:202–206CrossRefPubMed
15.
go back to reference Vlassara H, Palace MR (2002) Diabetes and advanced glycation endproducts. J Intern Med 251:87–101PubMed Vlassara H, Palace MR (2002) Diabetes and advanced glycation endproducts. J Intern Med 251:87–101PubMed
16.
go back to reference Neeper M, Schmidt AM, Brett J et al. (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:14998–15004PubMed Neeper M, Schmidt AM, Brett J et al. (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:14998–15004PubMed
17.
go back to reference Brett J, Schmidt AM, Yan SD et al. (1993) Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143:1699–1712PubMed Brett J, Schmidt AM, Yan SD et al. (1993) Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143:1699–1712PubMed
18.
go back to reference Hofmann MA, Drury S, Fu C et al. (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97:889–901PubMed Hofmann MA, Drury S, Fu C et al. (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97:889–901PubMed
19.
go back to reference Bucciarelli LG, Wendt T, Rong L et al. (2002) RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 59:1117–1128CrossRef Bucciarelli LG, Wendt T, Rong L et al. (2002) RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 59:1117–1128CrossRef
20.
go back to reference Yan SD, Schmidt AM, Anderson GM et al. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889–9897PubMed Yan SD, Schmidt AM, Anderson GM et al. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889–9897PubMed
21.
go back to reference Schmidt AM, Hori O, Chen JX et al. (1995) Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96:1395–1403PubMed Schmidt AM, Hori O, Chen JX et al. (1995) Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96:1395–1403PubMed
22.
go back to reference Miyata T, Hori O, Zhang J et al. (1996) The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 98:1088–1094PubMed Miyata T, Hori O, Zhang J et al. (1996) The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 98:1088–1094PubMed
23.
go back to reference Schmidt AM, Stern DM (2000) RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. TEM 11:368–375CrossRefPubMed Schmidt AM, Stern DM (2000) RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. TEM 11:368–375CrossRefPubMed
24.
go back to reference Kislinger T, Fu C, Huber B et al. (1999) N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740–31749PubMed Kislinger T, Fu C, Huber B et al. (1999) N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740–31749PubMed
25.
go back to reference Valencia JV, Weldon SC, Quinn D et al. (2004) Advanced glycation endproduct ligands for the receptor for advanced glycation endproducts: biochemical characterization and formation kinetics. Anal Biochem 324:68–78CrossRefPubMed Valencia JV, Weldon SC, Quinn D et al. (2004) Advanced glycation endproduct ligands for the receptor for advanced glycation endproducts: biochemical characterization and formation kinetics. Anal Biochem 324:68–78CrossRefPubMed
26.
go back to reference Ades EW, Candal FJ, Swerlick RA et al. (1992) HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 99:683–690 Ades EW, Candal FJ, Swerlick RA et al. (1992) HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 99:683–690
27.
go back to reference Skehan P, Storeng R, Scudiero D et al. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107–1112PubMed Skehan P, Storeng R, Scudiero D et al. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107–1112PubMed
28.
go back to reference Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ (1992) Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci USA 89:2873–2877PubMed Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ (1992) Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci USA 89:2873–2877PubMed
29.
go back to reference Radoff S, Makita Z, Vlassara H (1991) Radioreceptor assay for advanced glycosylation end products. Diabetes 40:1731–1738PubMed Radoff S, Makita Z, Vlassara H (1991) Radioreceptor assay for advanced glycosylation end products. Diabetes 40:1731–1738PubMed
30.
go back to reference Acton S, Resnick D, Freeman M, Ekkel Y, Ashkenas J, Kriegar M (1993) The collagenous domains of macrophage scavenger receptors and complement component C1q mediate their similar, but not identical, binding specificities for polyanionic ligands. J Biol Chem 268:3530–3537PubMed Acton S, Resnick D, Freeman M, Ekkel Y, Ashkenas J, Kriegar M (1993) The collagenous domains of macrophage scavenger receptors and complement component C1q mediate their similar, but not identical, binding specificities for polyanionic ligands. J Biol Chem 268:3530–3537PubMed
31.
go back to reference Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL (2001) Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280:E685–E694 Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL (2001) Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280:E685–E694
32.
go back to reference Boulanger E, Wautier MP, Wautier JL et al. (2002) AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 61:148–156CrossRefPubMed Boulanger E, Wautier MP, Wautier JL et al. (2002) AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 61:148–156CrossRefPubMed
33.
go back to reference Still AW, He C, Vlassara H (1999) Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells. Biochem Biophys Res Commun 256:549–556CrossRefPubMed Still AW, He C, Vlassara H (1999) Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells. Biochem Biophys Res Commun 256:549–556CrossRefPubMed
34.
go back to reference Bierhaus A, Chevion S, Chevion M et al. (1997) Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 46:1481–1490PubMed Bierhaus A, Chevion S, Chevion M et al. (1997) Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 46:1481–1490PubMed
35.
go back to reference Ivanov G, Kyurkchiev S (1998) Effect of advanced glycosylation end products on the activity of integrins expressed on U937 cells. Hum Immunol 59:325–330CrossRefPubMed Ivanov G, Kyurkchiev S (1998) Effect of advanced glycosylation end products on the activity of integrins expressed on U937 cells. Hum Immunol 59:325–330CrossRefPubMed
36.
go back to reference Prasad AS, Bao B, Beck FW, Sarkar FH (2002) Zinc enhances the expression of interleukin-2 and interleukin-2 receptors in HUT-78 cells by way of NF-kappaB activation. J Lab Clin Med 140:272–289CrossRefPubMed Prasad AS, Bao B, Beck FW, Sarkar FH (2002) Zinc enhances the expression of interleukin-2 and interleukin-2 receptors in HUT-78 cells by way of NF-kappaB activation. J Lab Clin Med 140:272–289CrossRefPubMed
37.
go back to reference She H, Xiong S, Lin M, Zandi E, Giulivi C, Tsukamoto H (2002) Iron activates NF-kappaB in Kupffer cells. Am J Physiol Gastrointest Liver Physiol 283:G719–G726PubMed She H, Xiong S, Lin M, Zandi E, Giulivi C, Tsukamoto H (2002) Iron activates NF-kappaB in Kupffer cells. Am J Physiol Gastrointest Liver Physiol 283:G719–G726PubMed
38.
go back to reference Hui YY, McAmis WC, Baynes JW, Schaeffer RC Jr, Wolf MB (2001) Effect of advanced glycation end products on oxidative stress in endothelial cells in culture: a warning on the use of cells studied in serum-free media. Diabetologia 44:1310–1317CrossRefPubMed Hui YY, McAmis WC, Baynes JW, Schaeffer RC Jr, Wolf MB (2001) Effect of advanced glycation end products on oxidative stress in endothelial cells in culture: a warning on the use of cells studied in serum-free media. Diabetologia 44:1310–1317CrossRefPubMed
Metadata
Title
Binding of receptor for advanced glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived advanced glycation end products
Authors
J. V. Valencia
M. Mone
C. Koehne
J. Rediske
T. E. Hughes
Publication date
01-05-2004
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1392-9

Other articles of this Issue 5/2004

Diabetologia 5/2004 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.